- Condition: Complications of Surgical and Medical Care: General Terms
Interventions: Other: Usual care; Other: Feedback of Performance; Other: Feedback of Performance + Health Psychology Informed Intervention
Sponsors: University of Dundee; University of Dundee; Chief Scientist Office of the Scottish Government; University of Strathclyde; Information Services Division, NHS Scotland
Not yet recruiting - verified May 2012 - Condition: Osteoarthrosis
Interventions: Device: MRI therapy; Device: MRI therapy (off)
Sponsors: NHS Grampian; NHS Grampian
Completed - verified May 2012 - Condition: Cervical Cancer
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Radiation: Radiotherapy; Drug: Cisplatin
Sponsors: University College, London; University College, London; Cancer Research UK
Not yet recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Propranolol; Drug: Placebo; Drug: Qvar 50; Drug: Qvar 100
Sponsors: University of Dundee; University of Dundee; Chief Scientist Office of the Scottish Government
Not yet recruiting - verified February 2012 - Conditions: Multiple Sclerosis; Fatigue
Interventions: Other: Cognitive behavioural therapy based self help; Other: Treatment as usual
Sponsors: University of Edinburgh; University of Edinburgh
Not yet recruiting - verified January 2012 - Condition: Acute Lung Injury
Intervention: Other: Microdose of NAP
Sponsors: University of Edinburgh; University of Edinburgh; Medical Research Council
Not yet recruiting - verified January 2012 - Condition: Stroke
Interventions: Drug: Tenecteplase; Drug: alteplase
Sponsors: NHS Greater Glasgow and Clyde; NHS Greater Glasgow and Clyde; University of Glasgow
Not yet recruiting - verified November 2011 - Condition: Metastatic Clear Cell Renal Cancer
Intervention:
Sponsors: Queen Mary University of London; Queen Mary University of London
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: olaparib; Drug: temozolomide; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Procedure: therapeutic conventional surgery
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention:
Sponsors: Centre for Research in Environmental Epidemiology, Spain; Centre for Research in Environmental Epidemiology, Spain; Katholieke Universiteit Leuven; University of Edinburgh; Royal Brompton & Harefield NHS Foundation Trust; University Medical Centre Groningen; University of Athens
Recruiting - verified October 2011 - Condition: Coronary Heart Disease
Intervention: Radiation: Computed tomography scan
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Recruiting - verified June 2006 - Condition: Sepsis
Intervention:
Sponsors: University of Aberdeen; University of Aberdeen; UK Intensive Care Society
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Oxford University Hospitals NHS Trust; Oxford University Hospitals NHS Trust; Cancer Research UK
Recruiting - verified December 2011 - Condition: Bronchiectasis
Intervention: Drug: Atorvastatin
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Recruiting - verified November 2011 - Condition: BRONCHIECTASIS
Intervention: Drug: ATORVASTATIN
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Drug: hydroxychloroquine; Drug: imatinib mesylate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Glasgow; Lynn McMahon; Medical Research Council; CRUK Trials unit Glasgow
Recruiting - verified November 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: glioblastoma multiforme multipeptide vaccine IMA950; Biological: sargramostim; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: vandetanib; Drug: Placebo
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Cardiff University
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Notch signaling pathway inhibitor MK0752; Drug: gemcitabine hydrochloride; Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: fludeoxyglucose F 18
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified February 2012 - Condition: Coronary Artery Disease
Intervention: Device: Radi pressure wire (pressure wire assessment)
Sponsors: Southampton University Hospitals NHS Trust; Southampton University Hospitals NHS Trust
Recruiting - verified July 2011 - Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012 - Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Wales Cancer Trials Unit
Recruiting - verified May 2011 - Condition: Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Recruiting - verified August 2009 - Condition: Ovarian Cancer
Interventions: Genetic: DNA methylation analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Scottish Gynaecological Cancer Study Group
Recruiting - verified July 2009 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide phosphate; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: molecular genetic technique; Other: mass spectrometry; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Sarcoma
Interventions: Genetic: microarray analysis; Genetic: molecular diagnostic method; Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Christie Hospital NHS Foundation Trust
Recruiting - verified April 2008 - Condition: Bronchiectasis
Interventions: Procedure: Chest physiotherapy; Procedure: Chest Physiotherapy + Exercise Program
Sponsors: NHS Lothian; NHS Lothian
Completed - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: abiraterone acetate; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Leeds Cancer Centre at St. James's University Hospital
Recruiting - verified June 2009 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: Cancer Research UK, Glasgow; Cancer Research UK, Glasgow
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: parenteral chemotherapy
Sponsors: National Cancer Institute (NCI); Warwick Medical School
Recruiting - verified November 2008 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338); Genetic: protein expression analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified May 2012 - Conditions: Anxiety Disorder; Long-term Effects Secondary to Cancer Therapy in Adults; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: cyproterone acetate; Drug: releasing hormone agonist therapy; Other: active surveillance; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Oxford Radcliffe Hospital
Active, not recruiting - verified October 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Medical Research Council; Cooperative Trials Group for Neuro-Oncology
Recruiting - verified May 2011 - Conditions: Hereditary Breast and Ovarian Cancer Syndrome; Lynch Syndrome
Interventions: Other: Telemedicine; Other: Face-to-Face
Sponsors: Duke University; Duke University; Susan G. Komen Breast Cancer Foundation
Completed - verified February 2012 - Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the TesticleCondition: Testicular Germ Cell Tumor
Interventions: Other: questionnaire administration; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Head and Neck Cancer
Interventions: Other: questionnaire administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: regional lymph node dissection; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); The Facial Surgery Research Foundation
Recruiting - verified July 2009 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: motexafin gadolinium; Drug: temozolomide; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With IfosfamideConditions: Chemotherapeutic Agent Toxicity; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: gene expression analysis; Genetic: polymorphism analysis; Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Malignant Mesothelioma
Interventions: Drug: bortezomib; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified August 2007 - Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2008 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Breast Cancer; Hypercalcemia of Malignancy; Metastatic Cancer; Musculoskeletal Complications; Pain
Interventions: Drug: zoledronic acid; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University of Leeds
Recruiting - verified November 2007 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Drug: arsenic trioxide; Drug: azacitidine; Drug: busulfan; Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: fludarabine phosphate; Drug: gemtuzumab ozogamicin; Drug: melphalan; Drug: tipifarnib; Genetic: DNA methylation analysis; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); The University of New South Wales
Recruiting - verified August 2008 - Condition: Oesophagogastric Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cisplatin; Drug: epirubicin hydrochloride; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: Medical Research Council; Professor David Cunningham; Cancer Research UK
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: pravastatin sodium
Sponsors: University College, London; University College, London
Recruiting - verified December 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: carmustine; Drug: cyclophosphamide; Drug: cytarabine; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: etoposide phosphate; Drug: ifosfamide; Drug: melphalan; Drug: prednisolone; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Martin-Luther-Universität Halle-Wittenberg
Recruiting - verified June 2007 - Conditions: Breast Cancer; Infertility; Menopausal Symptoms
Interventions: Drug: cyclophosphamide; Drug: goserelin acetate; Procedure: adjuvant therapy; Procedure: fertility assessment and management; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Anglo Celtic Cooperative Oncology Group
Recruiting - verified May 2007 - Condition: Pancreatic Cancer
Interventions: Biological: sargramostim; Biological: telomerase peptide vaccine GV1001; Drug: capecitabine; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); Royal Liverpool University Hospital
Recruiting - verified May 2009 - Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Renal Failure
Interventions: Drug: chemotherapy; Drug: dexamethasone; Procedure: plasmapheresis
Sponsors: National Cancer Institute (NCI); University of Glasgow
Recruiting - verified June 2007 - Conditions: Asthma; Smoking; Steroid Resistance; Corticosteroid Insensitivity
Intervention: Drug: oral steroid-dexamethasone
Sponsors: University of Glasgow; University of Glasgow; Chief Scientist Office of the Scottish Government
Completed - verified September 2008 - Conditions: Lung Cancer; Metastatic Cancer
Interventions: Drug: dexamethasone; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified January 2007 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Southampton University Hospitals NHS Trust
Recruiting - verified October 2011 - Conditions: Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer
Interventions: Drug: releasing hormone agonist therapy; Drug: transdermal estrogen
Sponsors: National Cancer Institute (NCI); Imperial College London
Recruiting - verified June 2008 - Conditions: Extragonadal Germ Cell Tumor; Teratoma; Testicular Germ Cell Tumor
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified May 2007 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Active, not recruiting - verified February 2006 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Condition: Prostate Cancer
Interventions: Drug: celecoxib; Drug: docetaxel; Drug: prednisolone; Drug: releasing hormone agonist therapy; Drug: zoledronic acid; Drug: abiraterone; Procedure: orchiectomy
Sponsors: Medical Research Council; Medical Research Council
Recruiting - verified March 2012 - Condition: Malignant Mesothelioma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified November 2006 - Conditions: Metastatic Cancer; Pain; Prostate Cancer
Intervention: Drug: ibandronate sodium
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Completed - verified June 2009 - Condition: Breast Cancer
Intervention: Drug: anastrozole
Sponsors: Queen Mary University of London; Jill Knox
Active, not recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Royal College of Obstetricians and Gynecologists
Recruiting - verified May 2007 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Drug: Anastrozole
Sponsors: Queen Mary University of London; Jill Knox; Cancer Research UK
Active, not recruiting - verified May 2012 - Condition: Kidney Cancer
Interventions: Biological: aldesleukin; Biological: recombinant interferon alfa; Drug: fluorouracil; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; University of Glasgow
Active, not recruiting - verified July 2011 - Condition: Cervical Cancer
Interventions: Procedure: conventional surgery; Procedure: neoadjuvant chemotherapy; Radiation: brachytherapy; Radiation: radiation therapy; Drug: cisplatin
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified March 2012 - Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: monoclonal antibody Ch14.18; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: melphalan; Drug: vincristine sulfate; Procedure: bone marrow ablation with stem cell support; Procedure: conventional surgery; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester
Recruiting - verified August 2010 - Condition: Anal Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University College London (UCL) Cancer Institute
Recruiting - verified March 2007 - Condition: Breast Cancer
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: docetaxel; Drug: epirubicin hydrochloride; Drug: fluorouracil; Genetic: microarray analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Swedish Breast Cancer Group; Swiss Group for Clinical Cancer Research; Anglo Celtic Cooperative Oncology Group
Active, not recruiting - verified January 2010 - Condition: Head and Neck Cancer
Interventions: Biological: epoetin alfa; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Trans-Tasman Radiation Oncology Group (TROG); Charite University, Berlin, Germany; Groupe Oncologie Radiotherapie Tete et Cou; Radius Hungaricus Oncology Group; Grup per l'Estudi dels Limfomes de Catalunya i Balears
Active, not recruiting - verified June 2006 - Condition: Melanoma (Skin)
Interventions: Biological: pegylated interferon alfa; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified October 2000 - Condition: Lymphoma
Interventions: Drug: chlorambucil; Drug: dexamethasone; Drug: fludarabine phosphate; Drug: mitoxantrone hydrochloride
Sponsors: National Cancer Institute (NCI); Lymphoma Trials Office
Active, not recruiting - verified March 2007 - Condition: Leukemia
Interventions: Drug: chlorambucil; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: fludarabine phosphate; Drug: prednisolone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Leukemia Research Fund; Medical Research Council
Active, not recruiting - verified January 2006 - Conditions: Extragonadal Germ Cell Tumor; Teratoma; Testicular Germ Cell Tumor
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: cisplatin; Drug: etoposide; Drug: paclitaxel
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012 - Condition: Neuroblastoma
Intervention: Procedure: surgical procedure
Sponsors: National Cancer Institute (NCI); Societe Internationale d'Oncologie Pediatrique
Recruiting - verified July 2007 - Condition: Brain and Central Nervous System Tumors
Intervention: Drug: temozolomide
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Completed - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: epirubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Medical Research Council
Active, not recruiting - verified December 2005 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012 - Condition: Leukemia
Interventions: Biological: recombinant interferon alfa; Drug: cytarabine; Drug: hydroxyurea
Sponsors: National Cancer Institute (NCI); Medical Research Council
Active, not recruiting - verified February 2008 - Condition: Melanoma (Skin)
Intervention: Biological: recombinant interferon alfa
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified November 2011
 |
Join Clinical Trials by University in Scotland, United Kingdom |
